Novo Nordisk's CagriSema demonstrates superior blood sugar and weight reduction compared to Wegovy in a recent diabetes trial. However, it may face challenges competing against Eli Lilly's Zepbound in the obesity market.
CagriSema’s blood sugar and weight reductions exceeded the company’s blockbuster Wegovy, yet the drug might still struggle to rival Lilly's Zepbound.
Original title: “Novo combination obesity shot meets goal in diabetes trial”